SUNNYVALE, Calif., Sept. 19, 2019 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) today published an
informational guide designed to help radiation oncology practices
understand the complexities of the much-anticipated proposed
Medicare & Medicaid reimbursement changes. The new guide —
available at www.accuray.com/apm/ — serves as an informational
tool for healthcare providers who find themselves balancing their
desire to invest in improved patient treatment technologies with
the disruptiveness of a new billing model. Titled, "Thriving Under
the Radiation Oncology Alternative Payment Model: A Definitive
Guide to a New Reality," the guide aims to help radiation oncology
professionals understand the changes outlined in the Radiation
Oncology – Alternative Payment Model (RO-APM).
"We believe that the proposed alternative payment model will
reshape economic realities and evolve clinical best practices for
radiation oncologists," said Joshua H.
Levine, President and Chief Executive Officer
of Accuray. "Accuray technologies uniquely empower the
clinical capabilities necessary to thrive under the proposed
reimbursement changes. We are ready to help our customers
understand how the RO-APM will likely impact the use of our
products in their practices."
The July 2019 announcement of the
RO-APM outlined a progressive course toward value-based care,
shifting reimbursement to prospective, episode-based payments and
providing equal base-rate compensation at the tumor-site-specific
level — regardless of technique or modality, number of
fractions delivered or setting of care. Among the immediately
evident impacts, the episodic payment model aligns patient,
provider and payer interests with a shift to delivering
hypofractionated radiotherapy wherever clinically appropriate —
which should firmly establish hypofractionation as an essential
treatment modality.
"Growing evidence demonstrates hypofractionation as a proven
treatment modality that delivers clinical outcomes as good as
conventional fractionation while dramatically reducing the number
of treatments — and dramatically lowering the total cost of care,"
said Levine. "As both the pioneer and the continued innovation
leader in hypofractionation, Accuray provides an unmatched set of
tools developed specifically to give radiation oncologists the
confidence they need to deliver safe, efficient and effective
hypofractionated treatments to their patients."
Accuray innovations in hypofractionated radiotherapy include two
of the most accurate and precise treatment delivery systems in the
industry — the CyberKnife® and Radixact®
Systems — capable of delivering hypofractionated SBRT treatments to
targets anywhere in the body. Sophisticated dose-sculpting
capabilities enable clinicians to create treatment plans with
significantly smaller margins and sharper dose gradients. Accuray
Synchrony® technology provides the industry's only fully
integrated motion synchronization solution, automatically and
precisely synchronizing treatment delivery with real-time target
motion.
"Accuray technologies are designed to provide clinicians with
the resources they need to achieve both their clinical efficacy and
ROI goals. With the proposed new payment model, we believe that
hypofractionated treatments will provide an increasingly important
means of accomplishing these goals," said Birgit Fleurent, Chief Marketing Officer of
Accuray. "The CyberKnife and Radixact Systems offer a unique
combination of capabilities such as dose-sculpting, multi-angle
delivery and motion synchronization, that make it easier to
successfully deliver hypofractionated treatments — a process
necessitating an extremely high degree of precision and accuracy.
Clinicians can feel confident they will be able to optimize patient
care during all stages of the treatment journey."
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to the expected impact of the
Radiation Oncology – Alternative Payment Model, including its
impact on clinical best practices, expectations regarding the role
and importance of hypofractionated treatments under the new payment
model, clinical applications, clinical experiences and results,
patient experiences, and patient outcomes. These forward-looking
statements involve risks and uncertainties. If any of these risks
or uncertainties materialize, or if any of the company's
assumptions prove incorrect, actual results could differ materially
from the results expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the company's ability to achieve widespread market
acceptance of its products; the company's ability to develop new
products or improve existing products to meet customers' needs; the
company's ability to anticipate or keep pace with changes in the
marketplace and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's annual report on Form 10-K, filed
with the Securities and Exchange Commission (the "SEC") on
August 23, 2019, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth
Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-educates-radiation-oncology-practices-on-the-potential-impact-of-the-proposed-alternative-payment-model-roapm-300921062.html
SOURCE Accuray Incorporated